Blade Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $13.8M

  • Investors
  • 8

Blade Therapeutics General Information

Description

Developer of novel anti-fibrotic therapies intended to revolutionize the treatment of fibrotic disease. The company's therapies address various fibrotic diseases and their underlying pathophysiology to potentially reverse the damage to tissue, enabling patients to get cured of the disease without any side effects.

Contact Information

Formerly Known As
FibroRX
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 50 Francisco Street
  • Suite 450
  • San Francisco, CA 94133
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 50 Francisco Street
  • Suite 450
  • San Francisco, CA 94133
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Blade Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 01-Jan-2023 $13.8M Completed Generating Revenue
10. PIPE 08-Nov-2021 Cancelled Generating Revenue
9. Reverse Merger 08-Nov-2021 Cancelled Generating Revenue
8. Later Stage VC (Series C) 23-Oct-2019 Completed Generating Revenue
7. Debt - General 08-Mar-2019 Completed Clinical Trials - Phase 2
6. Accelerator/Incubator Completed Clinical Trials - Phase 2
5. Accelerator/Incubator 30-Jun-2016 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 08-Jun-2016 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 06-Jul-2015 $6M $6.5M Completed Clinical Trials - Phase 2
2. Debt - General 01-May-2015 $500K $500K Completed Clinical Trials - Phase 2
To view Blade Therapeutics’s complete valuation and funding history, request access »

Blade Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Series C
Series B 43,000,000 $0.000100 $0.07 $1.05 $1.05 1x $1.05 39.26%
Series A 6,500,000 $0.000100 $0.09 $1 $1 1x $1 5.93%
To view Blade Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Blade Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel anti-fibrotic therapies intended to revolutionize the treatment of fibrotic disease. The company's th
Drug Discovery
San Francisco, CA
31 As of 2022

Boston, MA
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Blade Therapeutics Competitors (55)

One of Blade Therapeutics’s 55 competitors is IFM Therapeutics, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
IFM Therapeutics Venture Capital-Backed Boston, MA
NexImmune Formerly VC-backed Gaithersburg, MD
TScan Therapeutics Formerly VC-backed Waltham, MA
Galectin Therapeutics Corporation Norcross, GA
Apeptico Venture Capital-Backed Vienna, Austria
You’re viewing 5 of 55 competitors. Get the full list »

Blade Therapeutics Patents

Blade Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020323923-A1 Calpain inhibitors and uses thereof for treating neurological disorders Inactive 31-Jul-2019
CA-3148822-A1 Calpain inhibitors and uses thereof for treating neurological disorders Pending 31-Jul-2019
EP-4003336-A1 Calpain inhibitors and uses thereof for treating neurological disorders Inactive 31-Jul-2019
EP-4003336-A4 Calpain inhibitors and uses thereof for treating neurological disorders Inactive 31-Jul-2019
US-20220257570-A1 Calpain inhibitors and uses thereof for treating neurological disorders Inactive 31-Jul-2019 A61K31/433
To view Blade Therapeutics’s complete patent history, request access »

Blade Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Blade Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
OneVentures Venture Capital Minority
Bristol-Myers Squibb Corporation Minority
Deerfield Management Venture Capital Minority
Novartis Institutes for BioMedical Research Corporation Minority
MPM BioImpact Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Blade Therapeutics Acquisitions (1)

Blade Therapeutics’s most recent deal was a Merger/Acquisition with ATXCo. The deal was made on 25-Sep-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ATXCo 25-Sep-2019 Merger/Acquisition Biotechnology
To view Blade Therapeutics’s complete acquisitions history, request access »

Blade Therapeutics FAQs

  • When was Blade Therapeutics founded?

    Blade Therapeutics was founded in 2013.

  • Where is Blade Therapeutics headquartered?

    Blade Therapeutics is headquartered in San Francisco, CA.

  • What is the size of Blade Therapeutics?

    Blade Therapeutics has 31 total employees.

  • What industry is Blade Therapeutics in?

    Blade Therapeutics’s primary industry is Drug Discovery.

  • Is Blade Therapeutics a private or public company?

    Blade Therapeutics is a Private company.

  • What is Blade Therapeutics’s current revenue?

    The current revenue for Blade Therapeutics is .

  • How much funding has Blade Therapeutics raised over time?

    Blade Therapeutics has raised $127M.

  • Who are Blade Therapeutics’s investors?

    OneVentures, Bristol-Myers Squibb, Deerfield Management, Novartis Institutes for BioMedical Research, and MPM BioImpact are 5 of 8 investors who have invested in Blade Therapeutics.

  • Who are Blade Therapeutics’s competitors?

    IFM Therapeutics, NexImmune, TScan Therapeutics, Galectin Therapeutics, and Apeptico are some of the 55 competitors of Blade Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »